BioWorld

March 15, 2006

View Archived Issues

HCV Data Drop HGS’ Shares; ‘Not Slam-Dunk,’ Analyst Says

Mixed interim data from a pair of Phase II trials with its drug for hepatitis C virus sent Human Genome Sciences Inc.’s stock down 20.3 percent. (BioWorld Today) Read More

Argos, Novo In Deal Worth Up To $69M For Lupus Drug

Read More

Corautus Falls On Suspended Angina Trial; Offering Scuttled

Read More

XenoPort Advances XP13512 Into First Phase III RLS Study

Read More

Other News To Note

Read More

Clinic Roundup

Read More